Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2015 Aug 15

PMID 26271795

Citations 37

Authors

AnnaChiara Uccellatore

Stefano Genovese

Ilaria Dicembrini

Edoardo Mannucci

Antonio Ceriello

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

Citing Articles

Glucagon-like peptide-1 receptor agonists in neoplastic diseases.

Ji L, He X, Min X, Yang H, Wu W, Xu H Front Endocrinol (Lausanne). 2024; 15:1465881.

PMID: 39371922 PMC: 11449759. DOI: 10.3389/fendo.2024.1465881.

A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy.

Bellanca C, Augello E, Di Benedetto G, Burgaletto C, Cantone A, Cantarella G Front Pharmacol. 2024; 15:1406860.

PMID: 38957391 PMC: 11217182. DOI: 10.3389/fphar.2024.1406860.

Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications.

Tudurachi B, Anghel L, Tudurachi A, Sascau R, Zanfirescu R, Statescu C Biomedicines. 2024; 12(6).

PMID: 38927520 PMC: 11201699. DOI: 10.3390/biomedicines12061314.

Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.

Herman R, Schmidt H Physiol Behav. 2024; 281:114565.

PMID: 38663460 PMC: 11128349. DOI: 10.1016/j.physbeh.2024.114565.

A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy.

Syed O, Jancic P, Knezevic N Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375749 PMC: 10304825. DOI: 10.3390/ph16060801.

References

Dungan K, Tofe Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W . Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951):1349-57. DOI: 10.1016/S0140-6736(14)60976-4. View

Linnebjerg H, Park S, Kothare P, Trautmann M, Mace K, Fineman M . Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008; 151(1-3):123-9. DOI: 10.1016/j.regpep.2008.07.003. View

Bergenstal R, Wysham C, MacConell L, Malloy J, Walsh B, Yan P . Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010; 376(9739):431-9. DOI: 10.1016/S0140-6736(10)60590-9. View

. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View

Seino Y, Min K, Niemoeller E, Takami A . Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012; 14(10):910-7. PMC: 3466411. DOI: 10.1111/j.1463-1326.2012.01618.x. View

Vilsboll T, Brock B, Perrild H, Levin K, Lervang H, Kolendorf K . Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008; 25(2):152-6. DOI: 10.1111/j.1464-5491.2007.02333.x. View

Kendall D, Riddle M, Rosenstock J, Zhuang D, Kim D, Fineman M . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5):1083-91. DOI: 10.2337/diacare.28.5.1083. View

Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Agullo L, Cabestrero A . The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion. Cardiovasc Res. 2006; 70(2):274-85. DOI: 10.1016/j.cardiores.2006.02.011. View

Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2008; 373(9662):473-81. DOI: 10.1016/S0140-6736(08)61246-5. View

10.

Buse J, Henry R, Han J, Kim D, Fineman M, Baron A . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(11):2628-35. DOI: 10.2337/diacare.27.11.2628. View

11.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12):2638-43. DOI: 10.2337/dc06-0706. View

12.

Nauck M, Duran S, Kim D, Johns D, Northrup J, Festa A . A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2006; 50(2):259-67. DOI: 10.1007/s00125-006-0510-2. View

13.

Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I . Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005; 48(6):1168-72. DOI: 10.1007/s00125-005-1749-8. View

14.

Salehi M, Prigeon R, DAlessio D . Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011; 60(9):2308-14. PMC: 3161307. DOI: 10.2337/db11-0203. View

15.

Toft-Nielsen M, Damholt M, Madsbad S, Hilsted L, Hughes T, Michelsen B . Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86(8):3717-23. DOI: 10.1210/jcem.86.8.7750. View

16.

Amori R, Lau J, Pittas A . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2):194-206. DOI: 10.1001/jama.298.2.194. View

17.

Russell-Jones D, Cuddihy R, Hanefeld M, Kumar A, Gonzalez J, Chan M . Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012; 35(2):252-8. PMC: 3263915. DOI: 10.2337/dc11-1107. View

18.

. Standards of medical care in diabetes--2009. Diabetes Care. 2009; 32 Suppl 1:S13-61. PMC: 2613589. DOI: 10.2337/dc09-S013. View

19.

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

20.

Naslund E, Barkeling B, King N, Gutniak M, Blundell J, Holst J . Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999; 23(3):304-11. DOI: 10.1038/sj.ijo.0800818. View